Ibogaine treatment is not available in the United States. The question of where to get ibogaine treatment has one honest answer for North Americans: outside the country. The medicine has been Schedule I under federal law since 1970, and no state has created a therapeutic exemption. The two legal destinations are Canada — where ibogaine is not listed under the Controlled Drugs and Substances Act — and Mexico, where it is also unscheduled. Vancouver, BC is 45 minutes north of the Washington border.
Ibogaine is not listed under Canada’s Controlled Drugs and Substances Act and is also unscheduled in Mexico — the two legal destinations for most North Americans. In the United States, it has been Schedule I since 1970. Vancouver, BC is 45 minutes north of the Washington border. Both require mandatory cardiac screening before any ceremony. Neither is appropriate for people with QT prolongation on EKG, active SSRIs or SNRIs, active psychosis, severe liver disease, or pregnancy.
Why ibogaine treatment does not exist in the United States
Ibogaine was placed on Schedule I in 1970 — alongside heroin and LSD — before any clinical research on the compound existed. The classification was based on its psychoactive properties, not on harm data, and it was made without knowledge of what the research would eventually show.
What has accumulated since is difficult to reconcile with a Schedule I classification. The 2023 Stanford study published in Nature Medicine treated 30 special operations veterans — people who had already tried conventional approaches for PTSD, depression, and traumatic brain injury without success. At one month post-treatment: PTSD symptoms reduced by 88%, depression by 87%, and anxiety by 81%. Texas subsequently committed $50 million USD to clinical ibogaine trials across four institutions: UTMB, UTHealth Houston, Texas A&M, and Baylor University.
None of this has changed the federal schedule. No ibogaine treatment centre operates legally in the United States. No state has created an exemption. The Texas funding is for research, not treatment access, and the timeline for any federal rescheduling is not established. If you are in the United States and want ibogaine treatment legally, you need to leave the country.
Canada: unscheduled and close to the border
Ibogaine is not listed under Canada’s Controlled Drugs and Substances Act. The regulatory status is unscheduled rather than approved — possession, provision, and administration are legal in a therapeutic context without requiring special exemptions.
For Americans, the logistics are accessible. Vancouver, BC is 45 minutes north of the Washington State border at the Peace Arch crossing — a 2.5-hour direct flight from Seattle, Portland, or San Francisco, and reachable from most US cities without a connecting flight. The border crossing returning to the United States is routine: you are not transporting an illegal substance, and the treatment occurred in Canada, legally. What requires planning is the recovery period. The 12–24 hour ceremony is followed by 2–3 days of supervised recovery, during which travel is not appropriate. A travel companion is strongly recommended.
A complete programme at Transcend in Vancouver covers pre-ceremony screening (12-lead EKG, blood panel, medication review, psychiatric history), the 12–24 hour active ceremony under continuous cardiac monitoring with an on-site physician, 2–3 days of supervised post-ceremony recovery, and initial integration support before departure. Cost ranges from $2,000–$5,000 CAD depending on what the individual requires. Integration coaching — $150–$300 CAD per session — continues remotely after you return home.
For a detailed breakdown of what the Canadian programme involves day by day, the ibogaine treatment in Canada guide covers arrival, screening, ceremony, recovery, and departure logistics. What each cost component covers is explained in the ibogaine cost guide.
Mexico: more providers, wider quality range
Mexico has a larger concentration of ibogaine providers than Canada. Ibogaine is also unscheduled federally in Mexico, and the provider market reflects that: more options, more variation. For Americans in the Southwest, it is geographically competitive with Canada — Tijuana is a short trip from San Diego, and several clinics operate in Baja California and Sonora.
The tradeoff is consistency. Mexico’s ibogaine market runs from medically rigorous operations to facilities that have removed safety infrastructure to reduce costs. The price range is $4,000–$12,000+ USD depending on what is included — and the variation reflects not location or amenities, but clinical infrastructure. Providers at the low end of that range have typically removed what costs the most to include: an on-site physician for the full 12–24 hours, continuous cardiac monitoring during ceremony, or the depth of pre-ceremony screening.
Providers charging significantly below market rate are almost always reducing safety infrastructure, not being generous. The cost of a physician, cardiac monitoring equipment, blood panels, and the medicine itself is real. When the number is low enough to seem like a good deal, something in the clinical programme has been removed. Understanding what that something is matters before the price does.
The Stanford study that found 88% reductions in PTSD symptoms was conducted at a clinic in Mexico — the country is not the limiting factor. The question is which specific provider operates at the standard the evidence was produced under. The MAPS ibogaine research overview provides context on clinical standards. The guide on ibogaine treatment facilities covers what a responsible provider looks like regardless of country.
What a legitimate provider must have
These criteria apply in Canada, Mexico, and any other country. They are not preferences or quality indicators — they are the minimum requirements for a medically appropriate setting.
12-lead EKG before ceremony. Ibogaine prolongs the QT interval. Extended QT beyond certain thresholds creates conditions for potentially fatal arrhythmias during the active experience. The EKG identifies this before ceremony, which is the only point at which it can be acted on. Most ibogaine-related fatalities documented in the peer-reviewed medical literature involve undetected or unmonitored QT prolongation. A provider that does not require an EKG before confirming a ceremony date is not operating safely.
Physician on-site for the full 12–24 hour ceremony. Not on call. Not reachable by phone. Physically present throughout. The active period is when cardiac risk is highest, and responding to a cardiac event requires being in the room.
Continuous ECG monitoring throughout ceremony. Not an initial check at dosing. Continuous monitoring that allows the on-site physician to see cardiac status in real time and act on changes as they occur.
Integration programme with substance.Noribogaine — ibogaine’s active metabolite — sustains elevated neuroplasticity for weeks to months after ceremony. The neuroplasticity window is when new patterns are most accessible. Whether anything lasting results from it depends on what is structured around it. Providers who close the conversation at discharge are not providing ibogaine treatment. Ask specifically what their integration programme includes, who delivers it, and for how long it runs.
Ask any provider these questions before booking. Those operating appropriately answer concisely and specifically. Promotional language in response to clinical questions is its own kind of answer.
Who cannot access ibogaine treatment anywhere
Not everyone who applies is an appropriate candidate. Some learn this during the screening process. The conversation that ends with “this is not the right path for you at this moment” is one of the most important things a responsible provider does. People who have found a thread of hope after years of failed treatment do not receive that answer easily. Saying it clearly — without softening it — is an act of care, not rejection.
Absolute contraindications — conditions that disqualify regardless of location or provider:
- QT prolongation on EKG, significant cardiac arrhythmia, or recent myocardial infarction
- Current SSRIs or SNRIs without a completed, medically supervised taper to zero — serotonin syndrome risk is real and potentially fatal, and no case is an exception to this rule
- Methadone without a supervised transition protocol
- Active psychosis or a schizophrenia-spectrum disorder
- Severe liver or kidney disease
- Lithium and most antipsychotics
- Pregnancy
Some of these are permanent disqualifiers. Others — the SSRI taper, for instance — are resolvable with physician supervision over 2–4 weeks. The medical screening process is where that determination is made. If you have a cardiac history or are on any of the medications listed above, the first step is a conversation, not an application.
Someone in acute psychiatric crisis is also not an appropriate candidate at this time, regardless of how urgently they want access. The experience amplifies what is present — entering it in a state of acute instability does not produce stability.
Is this the right path for you?
If you are a realistic candidate — no cardiac contraindications, medications manageable through a supervised taper, no active psychosis — the starting point is understanding what the programme involves. The ceremony page describes the full process at Transcend. The FAQ covers the most common questions about preparation, logistics, and what to expect. If you are ready to find out whether you qualify, you can submit an application. Every application receives a personal response within 2–3 business days.
If you have already completed ceremony elsewhere and are looking for continuing support, integration coaching is available remotely at $150–$300 CAD per session. You do not need to have worked with Transcend previously to access it.
For questions before applying, reach out at jake.nylund@gmail.com.